Targeting the complement system in ANCA-associated vasculitis management. [PDF]
de Groot K.
europepmc +1 more source
Betere medicijnen, vaccinaties tegen griep en het voorkomen van trombose zijn van belang voor patiënten met ANCA geassocieerde vasculitis (AAV) zoals de ziekte van Wegener. Het belangrijkste kenmerk van deze groep van ziekten is de ontsteking van kleine en middelgrote bloedvaten, die ontstaat doordat de afweer zich tegen het eigen lichaam richt.
openaire +1 more source
The overlap of ANCA associated vasculitis with Sjögren's syndrome in elderly male patient: a case report and literature review. [PDF]
Zhu M +7 more
europepmc +1 more source
The Complement System in ANCA-Associated Vasculitis: Mechanistic Insights, Therapeutic Horizons, and Unmet Clinical Needs. [PDF]
Sunmboye K, Millan P.
europepmc +1 more source
Impact of ANCA specificity on risk of cardiovascular events and death in ANCA-associated vasculitis. [PDF]
Idoate Lacasia J +22 more
europepmc +1 more source
Pituitary involvement in ANCA-associated vasculitis: Case report and literature review. [PDF]
Chen X +6 more
europepmc +1 more source
Immune checkpoint imbalance in ANCA-associated vasculitis: insights into disease activity and precision immunotherapy. [PDF]
García-Serrano L +2 more
europepmc +1 more source
Addressing clinical challenges in ANCA-associated vasculitis with real-world evidence. [PDF]
Jayne D.
europepmc +1 more source
Resolution of PR3-ANCA-associated vasculitis after antibiotic treatment of subacute bacterial endocarditis: a case report. [PDF]
Carter KS +4 more
europepmc +1 more source
Editorial: ANCA-associated vasculitis treatment: outcomes and complications. [PDF]
Crnogorac M +3 more
europepmc +1 more source

